Boston Scientific’s third-quarter 2020 revenue total is higher than Wall Street analysts expected it to be, but it is still lower than it was a year ago due to the slowdown in procedures caused by the pandemic.
The company generated nearly $2.7bn in sales during the third quarter of 2020, representing a 2.5% decline on an operational basis and 5.7% an organic basis compared to the third quarter of 2019, the company reported on 28 October
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?